Dementia – including Alzheimer’s disease and frontotemporal dementia (FTD) – represents a significant global healthcare challenge, with substantial personal and economic burden. As the therapeutic landscape evolves with emerging disease-modifying therapies, real-world evidence provides unique insights to support clinical strategies, inform healthcare decisions, and highlight unmet clinical needs.
Adelphi Real World’s Disease Specific Programmes (DSPs) are purpose-built to address these challenges.
Our Cognition DSPs provide comprehensive, real-world insights into diagnostic pathways, treatment decision-making and patient experiences. By engaging directly with neurologists, geriatricians, psychiatrists, patients, and caregivers, our DSPs deliver granular perspectives on:
Diagnostic Testing & the Clinical Care Pathway
Understand real-world diagnostic strategies, including prevalence of advanced biomarker testing, and key stakeholders in the clinical care pathway of patients with dementia.
Treatment Sequencing & Management Patterns
Understand real-world treatment decisions across cognitive condition types, disease stages, and healthcare systems – capturing adoption of emerging therapies and treatment decision pathways in routine dementia practice.
Physician Decision-Making
Explore the clinical reasoning behind treatment choices, factors influencing therapy selection in across disease stages, behavioural and cognitive symptom management strategies, and approaches to disease monitoring and functional assessment.
Patient & Caregiver Experiences & Outcomes
Capture real-world efficacy and satisfaction with treatment, patient and caregiver-reported quality of life outcomes, support needs and lived experiences in everyday clinical settings – bridging the gap between trial data and real-world patient and caregiver experience.
Emerging Unmet Needs
Uncover persistent treatment challenges, gaps in disease management, caregiver support barriers, and opportunities for therapeutic innovation to better support patients with dementia.
Cognitive Disease Specific Programmes (DSP) Portfolio
Why Partner With Adelphi Real World for Cognitive Conditions and Dementia Research?
Extensive Global Coverage
Our DSP network spans multiple countries, providing robust insights into dementia practice, treatment adoption, diagnostic approaches, and healthcare delivery across diverse healthcare systems.
Deep Clinical Expertise
With specialised knowledge of dementia and cognitive conditions, we ensure our data collection, analysis, and interpretation reflect the true complexity of disease management and of treating clinicians and supporting caregivers.
Evidence That Drives Impact
From clinical development to reimbursement and healthcare provider engagement, our dementia DSPs provide the credible, compelling evidence needed to influence decisions across the healthcare system.
Cognitive Disorders DSP Coverage
Let’s Get Started
- Schedule a Consultation: Meet with our teams to discuss how our DSPs can support your research across dementia and cognitive conditions.
- Get More Details:Want to explore our methodology, disease focus areas, global reach, caregiver insights? We’re here to answer your questions and provide customised information.
Adelphi Real World brings together real-world expertise, disease insight, and global reach to help you succeed in dementia research. Let’s collaborate to advance evidence and improve outcomes for patients with cognitive conditions and dementia.
Contact us today using the form below.
Conferences Attending
Observational Research